The short version of carcinogenicity fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-27. Anything still debated is marked as such rather than presented as settled.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Some of the problems in Dalton's method were corrected by Joseph-Louis Gay-Lussac and Amedeo Avogadro. They developed ratio laws for gases similar to the laws developed for chemicals by Proust and Dalton. In 1811, Avogadro proposed that equal volumes of any two gases, at equal temperature and pressure, contain equal numbers of molecules (in other words, the mass of a gas's particles does not affect the volume that it occupies). Avogadro's hypothesis, now usually called Avogadro's law, provided a method for deducing the relative weights of the molecules of gaseous elements, for if the hypothesis is correct relative gas densities directly indicate the relative weights of the particles that compose the gases. This way of thinking led directly to a second hypothesis: the particles of certain elemental gases were pairs of atoms, and when reacting chemically these molecules often split in two. For instance, the fact that two liters of hydrogen will react with just one liter of oxygen to produce two liters of water vapor (at constant pressure and temperature) suggested that a single oxygen molecule splits in two in order to form two molecules of water. This give the correct formula of water, H2O, not HO. Avogadro measured oxygen's atomic weight to be 15.074.
The cellular reproduction process of meiosis was discovered by Oscar Hertwig in 1876. Mitosis was discovered several years later in 1882 by Walther Flemming. Hertwig studied sea urchins, and noticed that each egg contained one nucleus prior to fertilization and two nuclei after. This discovery proved that one spermatozoon could fertilize an egg, and therefore proved the process of meiosis. Hermann Fol continued Hertwig's research by testing the effects of injecting several spermatozoa into an egg, and found that the process did not work with more than one spermatozoon. Flemming began his research of cell division starting in 1868. The study of cells was an increasingly popular topic in this time period. By 1873, Schneider had already begun to describe the steps of cell division. Flemming furthered this description in 1874 and 1875 as he explained the steps in more detail. He also argued with Schneider's findings that the nucleus separated into rod-like structures by suggesting that the nucleus actually separated into threads that in turn separated. Flemming concluded that cells replicate through cell division, to be more specific mitosis. Matthew Meselson and Franklin Stahl are credited with the discovery of DNA replication. Watson and Crick acknowledged that the structure of DNA did indicate that there is some form of replicating process. However, there was not a lot of research done on this aspect of DNA until after Watson and Crick. People considered all possible methods of determining the replication process of DNA, but none were successful until Meselson and Stahl.
Cyclodextrins were called "cellulosine" when first described by A. Villiers in 1891. Soon after, F. Schardinger identified the three naturally occurring cyclodextrins: α, β, and γ, referred to as "Schardinger sugars". For 25 years, between 1911 and 1935, Hans Pringsheim in Germany was the leading researcher in this area, demonstrating that cyclodextrins formed stable aqueous complexes with many other chemicals. By the mid-1970s, each of the natural cyclodextrins had been structurally and chemically characterized and many more complexes had been studied. Since the 1970s, extensive work has been conducted by Szejtli and others exploring encapsulation by cyclodextrins and their derivatives for industrial and pharmacologic applications. Among the processes used for complexation, the kneading process seems to be one of the best.
Sources: en.wikipedia.org
The Blood resource focus on the individual protein levels in blood of both healthy individuals and patients diagnosed with various diseases. Here you can explore: - The individual protein levels in blood from healthy individuals and patients diagnosed with diseases. - The longitudinal blood protein levels in healthy individuals during two years. - The longitudinal blood protein levels in children through puberty. - The effect of age, BMI and sex on the individual protein levels in blood. - The levels of plasma proteins using immune assays and mass spectrometry. The Subcellular resource of the Human Protein Atlas provides high-resolution insights into the expression and spatiotemporal distribution of proteins encoded by 13603 genes (67% of the human protein-coding genes) as well as predictions for an additional 3459 secreted- or membrane proteins, covering a total of 17062 genes (85% of the human protein-coding genes). For each gene, the subcellular distribution of the protein has been investigated by immunofluorescence (ICC-IF) and confocal microscopy in up to three different cell lines, selected from a panel of 42 cell lines used in the subcellular resource. Upon image analysis, the subcellular localization of the protein has been classified into one or more of 35 different organelles and fine subcellular structures. For some genes, the protein has also been stained in up to three ciliated cell lines, induced pluripotent stem cells (iPSCs) and/or in human sperm cells.
For example, in biochemistry it is widely used to separate charged molecules such as proteins. An important area of the application is extraction and purification of biologically produced substances such as proteins (amino acids) and DNA/RNA. Ion-exchange processes are used to separate and purify metals, including separating uranium from plutonium and the other actinides, including thorium, neptunium, and americium. This process is also used to separate the lanthanides, such as lanthanum, cerium, neodymium, praseodymium, europium, and ytterbium, from each other. The separation of neodymium and praseodymium was a particularly difficult one, and those were formerly thought to be just one element didymium – but that is an alloy of the two. There are two series of rare-earth metals, the lanthanides and the actinides, both of whose families all have very similar chemical and physical properties. Using methods developed by Frank Spedding in the 1940s, ion-exchange processes were formerly the only practical way to separate them in large quantities, until the development of the "solvent extraction" techniques that can be scaled up enormously. A very important case of ion-exchange is the plutonium-uranium extraction process (PUREX), which is used to separate the plutonium (mainly [[plutonium-239|239Pu) and the uranium (in that case known as reprocessed uranium) contained in spent fuel from americium, curium, neptunium (the minor actinides), and the fission products that come from nuclear reactors. Thus the waste products can be separated out for disposal.
Tina Ruth Coldham. Participation, Involvement and Engagement Advisor, NIHR. For services to Inclusive Patient and Public Involvement in Research. ShelleyJane Coleman. For services to the community in Plymouth, Devon. Robert John Collins. Founder, Pass It On Young Sports Voluntary Youth Organisation. For services to Young People and to Sport. Geraldine Constable. For services to the community in Hailsham and Eastbourne, East Sussex. Rev. Canon Diane Veronica Cookson. For services to St. Saviour's Parish Church and to the community in Stockport, Greater Manchester. Reginald John Cording. For services to the community in Barley, Hertfordshire. Jon-Paul Kitson Cornforth. For services to the community in Rotherham, South Yorkshire, particularly during Covid-19. Margaret Cortis. For voluntary and charitable services to the community in Truro, Cornwall. Robert David Cotterill. For services to Business and to the community in Derbyshire. Chico Cheikh Sadibou Coulibaly. Regional Manager Waterloo, South Western Railway. For services to the State Funeral of Her Majesty Queen Elizabeth II. Noel Desmond Cronin. Founder, Talking Pictures TV. For services to Television Broadcasting. Jill Elaine Crook. Director, Nursing, Professional and System Development, NHS England (South West). For services to Transforming Care, Learning Disability and Autism. David Cupples. For services to the community in County Tyrone. John Andrew Daley. For services to Young People and to the community in Sheffield, South Yorkshire. Anita Davenport-Brooks. Group Human Resources Manager, Lander Automotive.
Exothermic chemical reactions in closed systems do not change mass, but do become less massive once the heat of reaction is removed, though this mass change is too small to measure with standard equipment. In nuclear reactions, the fraction of mass that may be removed as light or heat, i.e. binding energy, is often a much larger fraction of the system mass. It may thus be measured directly as a mass difference between rest masses of reactants and (cooled) products. This is because nuclear forces are comparatively stronger than the Coulombic forces associated with the interactions between electrons and protons that generate heat in chemistry.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.